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ABSTRACT 
Objective: Mephedrone is a stimulant drug chemically related to amphetamine, with effects 
similar to those of amphetamine and cocaine. This study aims to analyse fatalities following 
ingestion of mephedrone in the UK amongst 16-24 year olds in 2009-13, providing an update 
on data presented at the 2nd International Conference on Novel Psychoactive Substances. 
Methods: A literature search was undertaken to identify published information on 
pharmacology, toxicity, and fatalities associated with mephedrone. Fatalities involving 
mephedrone were extracted from the National Programme on Substance Abuse Deaths 
database, which receives information on drug-related deaths from Coroners in the UK and 
Islands and other data suppliers. Selection criteria: deceased aged 16-24 at time of death; 
mephedrone directly implicated in the cause of death and/or mentioned in the Coroner’s 
verdict.  
Results: Thirty cases met the study criteria and, when known, all were of White ethnicity, 
most (85%) had a history of drug use and 73% were male. Two-thirds (63%) were accidental 
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poisonings. Mephedrone was used with other substances in most cases (87%); other 
substances were implicated in 60% of deaths.  
Conclusions: Mephedrone use can have potentially fatal consequences, especially in 
combination with other substances. Deaths in the 16-24 years age-group continue to occur 
from its use in the UK, despite it being a controlled drug. Health professionals and potential 
consumers should be alert to this risk.  
 
 
 
KEY WORDS: mephedrone; novel psychoactive substances; NPS; legal high; deaths; young 
people. 
ABBREVIATIONS: 
4-MA   4-Methylamphetamine 
BZP  Benzylpiperazine 
GHB  Gammahydroxybutyrate 
MDA  Methylenedioxyamphetamine 
MDMA Methylenedioxymethylamphetamine 
MDPV  Methylenedioxypyrovalerone 
TFMPP 3-Trifluoromethylphenylpiperazine monohydrochloride 
 
 
INTRODUCTION 
Mephedrone is a synthetic drug related to the naturally occurring stimulant cathinone found in 
the leaves of the khat plant (Catha edulis) which have been chewed and enjoyed socially for 
centuries in Africa for their stimulant properties (Kalix, 1990; Kalix, 1992). Mephedrone is 
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one of the several novel psychoactive substances (NPS; commonly known in the market 
by several terms such as: “designer drugs”, “herbal highs”, “legal highs”, “laboratory 
reagents”, and “research chemicals”), belonging to the class of synthetic cathinones 
(UNODC, 2013). To clarify and unify the terminology on this issue, the European Union 
legally defined the term ‘novel psychoactive substance’ as a new narcotic or 
psychotropic drug, either  in a pure form or a preparation, that is not scheduled under 
the Single Convention on Narcotic Drugs of 1961 or the Convention on Psychotropic 
Substances of 1971, but which may pose a public health threat comparable to that posed 
by substances listed in those conventions (Council of the European Union, 2011). This 
class of substances has played an increasingly important role in terms of both NPS use 
and related fatalities, being implicated in 53.8% (92/171) NPS-related deaths in the UK 
recorded by the National Programme on Substance Abuse Deaths (NPSAD) in 2009-
2012 (Corkery et al., 2014; Ghodse et al., 2013). The importance of synthetic cathinones 
in the European market is still evident (EMCDDA, 2014:14).   
Mephedrone use became popular in the United Kingdom (UK) during 2009, and adverse 
health effects including poisonings and fatalities gave rise to serious concern amongst 
the relevant UK authorities. These led to its control as a Class B substance under the UK 
Misuse of Drugs Act 1971 in April 2010 (ACMD, 2010), and also across the European 
Union. While mephedrone has now been banned, legal high manufacturers are 
increasingly altering the chemical formulas of banned legal highs to avoid prohibitions 
on specific substances. In response, the UK Advisory Council on the Misuse of Drugs 
(ACMD) suggested that legislation should be used either to ban specific chemicals as 
they emerge, or to make it illegal to produce substances with similar effects to banned 
drugs. (ACMD, 2011). 
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 The issue of NPS is not recent, but has become important because of several factors 
including: chemical technologies, market availability, internet supply, price and others. 
NPS are often marketed as “not for human consumption” and may be described as 
“plant food‟, “fish food”, “room odouriser” or other terms. Some materials are sold as 
“legal high” products with a trade name but no indication of the active ingredients. 
The harms of NPS may be physical (intrinsic to the drug) or social in nature and 
unfortunately there is an upward trend in admissions, due to NPS drug toxicity, for both 
hospital and pre-hospital presentations (Wood et al, 2014). The ACMD (2011) 
recommends that the government implements strategies to decrease the request for NPS 
by including NPS in substance misuse education in schools and developing prevention 
initiatives. Mephedrone is often advertised as bath salts, plant food, insecticides, novelty 
items, chicken feed additives, or research chemicals, with products being sold with 
names like “Meow Meow”, “Meph”, “TopCat”, “4-MMC”, etc. (Winstock, et al., 2010). 
Warnings that the contents are not for human consumption are added to packaging in 
an attempt to escape legal and civil sanctions. 
  
Pharmacology 
The pharmacology of mephedrone is characterised by monoamine reuptake inhibition 
involving the dopamine, norepinephrine and serotonin transporters thus accounting for their 
cocaine- and amphetamine-like effects (Meltzer et al., 2006; Dargan et al., 2011).  The 
dopamine (DAT) norepinephrine (NET) and serotonin transporters (SERT) strongly regulate 
the amount of neurotransmitters released into the synaptic cleft, influencing the extent and 
duration of neuronal signals. Mephedrone also increases presynaptic release of the same 
monoamines through changes in vesicular pH and inhibition of the vesicular monoamine 
transport receptor (VMAT2) which is located on the vesicular membrane and responsible for 
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monoamine uptake into the vesicles for storage (Cozzi et al., 1999). In addition, mephedrone 
exhibits relevant (<10 mM) 5-HT2A receptor binding (López-Arnau et al., 2012) and binds to 
α1-adrenergic receptors (Simmler et al., 2013). 
 
Routes of administration and dosages 
Mephedrone is most commonly used by nasal insufflation/snorting of powder; or oral 
ingestion of powder dissolved in liquid,  or ‘bombing’ (wrapped in paper), or in capsule or 
tablet form (James et al., 2011; Carhart-Harris et al., 2011). Rectal administration, inhalation, 
and intramuscular or intravenous injection have also been described (Psychonaut Web 
Mapping Research Group, 2009; Newcombe, 2009). Its physical characteristics (instability) 
make mephedrone unsuitable for smoking. Based on user reports, the onset of psychoactive 
effects after oral ingestion is approximately 15–45 min with duration of 2–4 h. Onset after 
insufflation is 10–20 min with duration of effect of about 1–2 h; intravenous users report 
symptoms peaking at 10–15 min with 30 min duration of desired effects (EMCDDA, 2010; 
Newcombe, 2009). Mephedrone dosages: snorting 25 - 75 mg (Sumnall & Wooding, 2009); 
oral 150- 250 mg (Psychonaut Web Mapping Research Group, 2009); intramuscularly 150-
250 mg (Wood et al., 2010); intravenous doses are one half or two-thirds of the oral dose; 
rectal about 100 mg (Psychonaut Web Mapping Research Group, 2009).    
 
Typical users and effects 
Mephedrone use became popular in the UK during 2009 among a wide population of older 
adolescents and young adults due, in part, to its desired psychoactive effects, cheapness, legal 
status, and easy availability online (Psychonaut Web Mapping Research Project, 2010). 
Young people can easily search the Internet without parental control (Tsitsika et al., 2009) 
and find many sites that emphasise the positive effects of this drug and minimise its negative 
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effects. Young people’s inexperience of drugs means exposure to different psychoactive drugs 
could increase vulnerability to accidents, fatal drug intoxications caused by consumption of 
multiple drugs, etc. (ACMD, 2011).  
 
Typical UK mephedrone consumers are young adults, mainly males, with a history of 
stimulant and polydrug use (Carhart-Harris et al., 2011). This profile is similar to that of 
consumers of typical amphetamine-type stimulants (including amphetamine, 
methylamphetamine, ecstasy, and ecstasy-type drugs) (De Letter et al. 2006). Over 40% of 
UK dance club drug users have reported the use of mephedrone (Winstock et al., 2011), and 
it is commonly used by patrons of UK and European nightclubs (Wood et al., 2012; 
Yamamoto et al., 2013). Mephedrone use has continued in the UK despite its prohibition.  
The 2012/13 sweep of the Crime Survey for England and Wales (Home Office, 2013) found 
that use of mephedrone among young adults aged 16 to 24 years fell from 3.3% in 2011/12 to 
1.6% in 2012/13. A self-selected sample of respondents reported a fall in use of the drug from 
19.5% to 13.8%, in part due to its unwanted effects on mental health (Winstock, 2013).  
 
Users report mephedrone’s effects as somewhere between amphetamine, cocaine and ecstasy 
(Measham et al., 2010). The desired psychological and behavioural effects reported by users 
include feelings of intense euphoria, increased energy, heightened concentration, 
moderate sexual arousal, intense stimulation and alertness, empathy/feelings of 
closeness, sociability and talkativeness, intensification of sensory experiences, and 
perceptual distortions (Winstock et al., 2011). These are similar to a range of NPS, either 
with stimulant (Schifano et al, 2005) and/or hallucinogenic (Ricci et al, 2011) properties, 
mephedrone may be associated with a number of both physical and psychopathological side 
effects especially reported in persons with psychiatric, cardiac or neurological issues, who 
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may have a higher risk of side-effects (Winstock et al., 2010). The most common adverse 
effects reported in mephedrone users who require medical care include: gastrointestinal 
symptoms (loss of appetite, dry mouth, nausea, vomiting) neurological signs (tremors, tense 
jaws, bruxism, headache, dizziness, seizures) and cardiovascular effects (tachycardia, elevated 
blood pressure, respiratory difficulties, chest pain, peripheral vasoconstriction; (Schifano et 
al., 2011), and psychiatric symptoms (anxiety, aggression, agitation, confusion, dysphoria, 
depression, irritability; time distortions, long-lasting hallucinations, paranoid delusions, short-
term psychosis, short-term mania; insomnia and nightmares; impaired short-term and working 
memory). Several studies have also shown that cardiovascular and central nervous system 
(CNS) effects of mephedrone are related to its stimulation of the catecholaminergic system, 
which can lead to severe acute intoxication and high risk of fatal consequences (Meltzer et al., 
2006; Durham, 2011). Withdrawal effects following mephedrone use most frequently include 
tiredness, insomnia, nasal congestion and impaired concentration (Winstock et al., 2011). 
 
Emergency department admissions and fatalities  
Although many individuals have presented at Emergency Departments (EDs) following 
exposure incidents and acute toxicity due to the ingestion of mephedrone, Wood et al. (2013) 
suggest that controlling mephedrone reduced the number of UK ED presentations with acute 
toxicity. Mephedrone is often used with other psychostimulants such as cocaine, 
amphetamine, benzylpiperazine, butylone, methylone or pentylone; such use is thought to 
enhance their stimulant and entactogen effects (Schifano et al., 2011). Mephedrone is 
sometimes used in association with alcohol or controlled substances including heroin 
(EMCDDA, 2010), cocaine, cannabis, ketamine (ACMD, 2010). Such drug combinations can 
result in fatal intoxication, as the co-occurrence of several stimulants might enhance both 
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dopaminergic and serotonergic stimulation, increasing the potential for serotonin 
syndrome and fatal intoxication to occur (Schifano et al., 2004). Most amphetamine, 
methylamphetamine and ecstasy victims die of polydrug ingestion (Schifano et al., 2010).  
 
Mephedrone-fatalities among young people have been described in several studies. The 
earliest case report was in 2008 of an 18-year-old Swedish woman, where mephedrone was 
the only substance detected post mortem (Morris, 2010). A 22 year old US male died of 
accidental multiple drug toxicity; mephedrone along with morphine, codeine, and 
doxylamine, was detected in post-mortem samples (Dickson et al., 2010). Two UK cases of 
two teenagers aged 18 and 19 years old who died after taking mephedrone were noted by 
Dyer (2010).  The death of a 19-year-old male who died of cardio-respiratory arrest after 
consuming an unknown quantity of mephedrone along with alcohol and “ecstasy” was 
reported together with a fatal intoxication of a 17 year old male where toxicological analysis 
disclosed mephedrone have been reported (Maskell et al., 2011). Cosbey et al. (2013) 
reported 32 mephedrone-related poisonings, including fatalities, predominantly among young 
adult males, in Northern Ireland; only two were attributed directly to mephedrone toxicity.   
 
The National Programme on Substance Abuse Deaths (NPSAD) has previously reported on 
60 UK mephedrone-fatalities in the UK, ages ranged from 14 to 64 years. Overall (n = 36 
where quantified) post mortem blood levels were mean = 1.59 mg/L, range = <0.01 – 22.0 
mg/L, excluding one outlier with a level of >2000 mg/L (Schifano et al., 2012; Corkery et al., 
2012a). Cosbey et al. (2013) noted that in fatal cases in which death was attributed directly to 
mephedrone toxicity alone, blood mephedrone concentrations were approximately 2.0 mg/L. 
This concentration is similar to the single case reported by Maskell et al. (2011), in which 
mephedrone was considered to be the primary cause of death (blood mephedrone 
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concentration of 2.24 mg/L) (Maskell et al. 2011). Moreover, Torrance et al. (2010) found 
that post-mortem blood concentrations detected in confirmed mephedrone-related deaths were 
between 0.13 and 22 mg/L. 
 
METHODS 
A literature review using the PubMed, PsycINFO, Embase and Medline databases was 
undertaken, focusing on mephedrone’s effects, pharmacology, toxicity, fatalities and public 
health harms related to its use in people aged 16-24 years. This age group was chosen because 
of its use in UK prevalence surveys and other indicators. 
 
Fatalities involving mephedrone were then extracted from the NPSAD database. The 
Programme has been collecting and analysing drug-related deaths in the UK since 1997 with 
Coroners and relevant regional authorities submitting information voluntarily on drug-related 
deaths (Corkery et al., 2014). To date, details of some 30,000 deaths have been received. 
 
For a case to qualify as a ‘mephedrone-related death’ for the purposes of this paper, it had to 
fulfil one or more of the following criteria: ‘mephedrone’ or ‘4-methylmethcathinone’ either 
implicated in the cause of death and/or mentioned in the Coroner’s verdict. The deceased had 
to be aged between 16 and 24 at time of death. This paper includes cases notified up to 
September 2013. 
 
Analyses were performed using IBM® SPSS® Statistics, version 19 for Windows™. 
Demographics, risk factors, and other categorical data were expressed as frequencies and 
percentages within groups.  
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RESULTS  
Up to September 2013, 30 cases meeting the study criteria had been notified, equating to 43% 
of notified mephedrone-related fatalities. The first death in this sample occurred in September 
2009 and the last in April 2013. Just over half (57%) occurred in England. The age in this 
group ranged from 17 to just under 25 years; mean age was about 20 years. Most cases were 
male (73%), lived with others (73%), and where their ethnicity was known (27/30), all 
were White. Of those with known employment status, 50% were employed. Amongst the 13 
whose drug use or addiction status was known, 11 were known drug users (Table 1). 
Where known, only one out of 17 cases had been prescribed drugs (citalopram and 
diazepam); in 13 cases this status was unknown. 
 
< Table 1 about here > 
 
Just under half (47%) died in a defined residential address (typically their own home or that of 
a friend) and one-quarter (27%) in hospital (Table 2). Where known (n = 24), the majority had 
used mephedrone recreationally: eight with a friend, three at a party, two during a night out, 
and one alone at home. In at least three cases, death followed ‘bombing’. Three individuals 
died in road traffic accidents; for two the drug could have affected their ability to drive. A 
drowning occurred as a result of impaired judgement following its consumption. Three deaths 
followed an argument or the ending of a relationship. In two cases suicide followed after 
changes in mood following consumption, and one as a result of depression. Two-thirds (63%) 
of cases were considered to be accidental or as the result of misadventure, with abuse of drugs 
in one case and drug dependence in another. There were three intentional and four possible 
suicides.  
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< Table 2 about here > 
 
In most cases (63%) accidental poisoning was the underlying cause of death, with 10% 
accounted for by intentional hanging. Other traumatic deaths involved unintentional hanging, 
drowning, and firearm and road traffic injuries. Accidental poisoning accounted for half 
(53%) of proximal (immediate) causes of death. This lower rate is due to more deaths from 
natural causes (10%). Here too, intentional hanging accounted for 10% of deaths (Table 3).  
 
< Table 3 about here > 
 
In only 4 cases was mephedrone the sole substance found at post mortem, whilst alcohol and 
mephedrone only were consumed in a further 4 cases (Table 4). Polydrug use with or without 
alcohol consumption occurred in all remaining cases (n = 22). The most common substances 
consumed were, in descending frequency: alcohol, benzodiazepines, piperazines, cocaine, 
opiates/opioids, amphetamine and ecstasy. 
 
< Table 4 about here > 
 
Post mortem mephedrone blood levels were available in 17/30 cases (Table 5). Where 
mephedrone was the only substance taken the levels were 0.190 and 3.300mg/L (mean 1.745 
mg/L). For cases (n = 6) where only mephedrone was implicated but multiple substances were 
consumed the mean level was 1.372 (range 0.070-2.240) mg/L. The mean level for cases 
where mephedrone was implicated with other substances (n = 9) was 0.518 (range 0.002 – 
2.000>) mg/L. The overall mean was 0.938 (range 0.002-3.300) mg/L. There was one outlier 
of 22.000 mg/L. Summary details for individual cases are given in Table 6. 
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< Table 5 about here > 
 
 
DISCUSSION  
This study highlights the dangers for young people aged 16-24 years of consuming 
mephedrone in association with alcohol, stimulants and/or CNS depressants. Typical victims 
in this study were male, White, with a history of previous drug use or dependence, and living 
with others. These demographics are similar to those found in our previous research on 
mephedrone (Corkery et al., 2012a; Schifano et al., 2012), as well as for deaths from 
stimulants more generally. 
 
Death occurred in a private home in just under half (47%) of cases, one quarter (27%) in 
hospital, and also in a variety of other locations, such as a street, river or park. The majority of 
cases followed recreational use of mephedrone leading to accidental overdoses/poisonings.  
 
Serious concern about the potential toxicity of this drug itself is confirmed by the occurrence 
of four deaths (13%) where mephedrone was implicated on its own. In a further 8 cases (27%) 
mephedrone was considered the sole drug implicated although other substances were present 
post mortem. Mephedrone was found to be implicated with other substances in 18 cases. On 
average, at least two other substances had been used (Table 5). Our findings here reinforce the 
continuing pattern of polysubstance use by young people. Many of these substances are 
stimulants (ecstasy, amphetamine, cocaine), piperazines (BZP, TFMPP) and other synthetic 
cathinones (methylone, MDPV). 
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According to the literature, other stimulants, such as amphetamine-like drugs, are frequently 
detected in toxicology reports of mephedrone-associated fatalities, suggesting that 
simultaneous use of synthetic cathinones with stimulants may amplify, in a synergic way, 
both dopaminergic and serotoninergic stimulation, and enhance the risk of death (Schifano et 
al., 2012). Indeed, one death (case 11) was attributed to Serotonin Toxicity Syndrome (with 
4-MA). The co-ingestion of CNS depressants appears to be another common feature of these 
deaths, specifically alcohol, benzodiazepines (mainly diazepam), and opiates/opioids. This 
aspect is a well-known risk factor for elevated risk of death (Ghodse et al., 2010).  
 
Where post mortem blood levels were available and excluding an outlier of 22.0 mg/L, the 
mean mephedrone concentration was 0.938 (range 0.0016-3.300) mg/L. This is in line with 
our previous findings (Corkery et al., 2012a) and those of Torrance et al. (2010), some of 
which cases are included on the NPSAD database. Lower concentrations were found in cases 
where other substances were implicated and/or consumed compared to cases of solely 
mephedrone consumption. This suggests that lower dosages of mephedrone can potentially 
cause/trigger serious adverse consequences when taken in combination with other substances.  
 
The formal conclusions by Coroners and their counterparts reflect the largely recreational 
circumstances of mephedrone use described here, i.e. accidental/misadventure (63%) and 
abuse of drugs (7%). We have previously noted growing concern about the addiction potential 
of synthetic cathinones (Schifano et al., 2012) and other worrying adverse effects on the 
mental state of individuals consuming mephedrone are worrying (Corkery et al., 2012a), 
including in this 16-24 years age-group. Here, we would highlight: (a) impaired judgement 
leading to fatal road traffic accidents and drowning; and (b) depression, paranoia and 
psychoses resulting in intentional self-harm leading to death, e.g. hanging (see Table 2 for 
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examples); (c) withdrawal from mephedrone was regarded as a contributory factor in one 
case.   
 
Study limitations 
 
Blood levels were only available to NPSAD in 17/30 cases; this limits the interpretation of 
post mortem mephedrone blood concentrations, but can be set beside results from our 
previous research. Due to the voluntary nature of reporting to NPSAD and the inquest 
procedures associated with most drug-related deaths, other mephedrone-related deaths may 
have occurred prior to the publication of this study but which have not yet been reported to 
the Programme as the inquests into such cases may have not yet been concluded. In most 
cases, mephedrone was identified in combination with other drugs; hence, it is difficult to 
describe here the exact role that mephedrone played in the reported fatalities in this age-
group. However, our previous research suggests that mephedrone can be fatally toxic on its 
own (Corkery et al., 2012a; Schifano et al., 2012). 
 
CONCLUSIONS 
This study describes the largest case-series of mephedrone-related fatalities in young people 
aged 16-24 years. It confirms that individuals in this age-group are at potential risk of fatal 
mephedrone toxicity, whether on its own or more likely in combination with other substances, 
or from adverse mental health issues/depression following its use. Despite being controlled in 
the UK since April 2010, mephedrone has caused/contributed to fatalities and continues to do 
so (at least 9 in this age-group in 2011-3); there may be more waiting to be notified. This fact 
underlines the need for health and other professionals, as well as potential consumers to be 
alert to the potentially fatal consequences of using mephedrone.   
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Table 1: Summary socio-demographic characteristics  of UK mephedrone-related deaths in 
young people aged 16-24 years, reported to NPSAD by September 2013 (N = 30) 
 
Characteristic Attribute Number %
Country of death England 17 56.7
 Wales 1 3.3
 Scotland 7 23.3
 Northern Ireland 5 16.7
Gender Male 22 73.3
 Female 8 26.7
Ethnicity White 27 90.0
 Not known 3 10.0
Employment status Employed 12 40.0
 Unemployed 8 26.7
 Student 4 13.3
 Not known 6 20.0
Living arrangements With others 22 73.3
 Alone 1 3.3
 Not known 7 23.3
History of drug use/dependence Yes 11 36.7
 No 2 6.7
 Not known 17 56.7
Prescribed psychoactive drugs Yes 1 3.3
 No 16 53.3
 Not known 13 43.3
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Table 2: Summary characteristics of UK mephedrone-related deaths in young people aged 16-
24 years, reported to NPSAD by September 2013 (N = 30) 
 
Characteristic Attribute Number %
Place of death Defined residential address (own home or home of 
friend/relative) 
14 46.7
 Hospital 8 26.7
 Street/road 3 10.0
 Open place 1 3.3
 Woodland 1 3.3
 River 1 3.3
 Not known 2 6.7
Coroner’s 
verdict/legal finding 
Accident/Misadventure 19 63.3
 Abuse of drugs 2 6.7
 Dependence on drugs  1 3.3
 Open/undetermined intent 4 13.3
 Suicide 3 10.0
 Other finding 1 3.3
Manner of death Accidental 23 76.7
 Undetermined intent 3 10.0
 Suicide 4 13.3
Circumstances 
leading to death 
Recreational – taken with friend (one case was on 
prescribed anti-depressants) 
8 26.7
 Recreational – taken at party 3 10.0
 Recreational – taken during evening out 2 6.7
 Recreational – taken at home with other substances 1 3.3
 Driving a car – fatal collision (inc. 2 where 
mephedrone could have affected ability to drive) 
3 10.0
 Drowning in river – impaired judgement following 
consumption 
1 3.3
 Suicide  by poisoning following end of relationship 
with boyfriend (no history of mental health 
issues/depression) 
1 3.3
 Self-harm by poisoning following argument with 
boyfriend (no history of mental health 
issues/depression) 
1 3.3
 Hanging following argument with girlfriend 
(contributed to by withdrawal from mephedrone) 
1 3.3
 Hanging after becoming ‘moody’ following 
consumption 
1 3.3
 Hanging following depression (history of depression) 1 3.3
 Suicide by shotgun after taking drugs at a party (no 
history of mental health issues/depression) 
1 3.3
 Not known 6 20.0
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Table 3: Cause of death in UK mephedrone-related deaths in young people aged 16-24 years, 
reported to NPSAD by September 2013 (N = 30) 
 
Cause of death Proximal 
(immediate) 
 Underlying  
 Number % Number % 
Accidental poisoning by drugs/alcohol 16 53.3 19 63.3
Poisoning of undetermined intent 0 0.0 1 3.3 
Drug overdose 1 3.3 0 0.0 
Stimulant abuse 0 0.0 1 3.3 
Intentional hanging 3 10.0 3 10.0
Hanging of undetermined intent 1 3.3 1 3.3 
Hanging 1 3.3 1 3.3 
Intentional self-harm by shotgun 1 3.3 1 3.3 
Drowning in river 1 3.3 1 3.3 
Bronchopneumonia 1 3.3 0 3.3 
Sudden cardiac death 1 3.3 0 3.3 
Disseminated intravascular coagulation 1 3.3 0 3.3 
Driver injured in collision with fixed or 
stationary object 
1 3.3 1 3.3 
Multiple injuries 2 6.7 1 3.3 
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 Table 4: Post mortem drug combinations found in UK mephedrone-related deaths in young 
people aged 16-24 years, reported to NPSAD by September 2013 (N = 30) 
 
Combination Number 
Mephedrone only 4 
Mephedrone + alcohol 4 
Mephedrone + amphetamine 1 
Mephedrone + diazepam 1 
Mephedrone + GHB 1 
Mephedrone + 4-MA 1 
Mephedrone + alcohol + cocaine 1 
Mephedrone + alcohol + diazepam 1 
Mephedrone + alcohol + morphine 1 
Mephedrone + alcohol + TFMPP 1 
Mephedrone + cocaine + methylone 1 
Mephedrone + diazepam + cannabis 1 
Mephedrone + diazepam + citalopram 1 
Mephedrone + MDMA + BZP 1 
Mephedrone + morphine + cannabis 1 
Mephedrone + alcohol + amphetamine + cocaine 1 
Mephedrone + alcohol + amphetamine + diazepam 1 
Mephedrone + BZP + TFMPP + diazepam 1 
Mephedrone + alcohol + cannabis + mirtazapine + propranolol 1 
Mephedrone + amphetamine + BZP + TFMPP + chlorpheniramine 1 
Mephedrone + BZP + TFMPP + cannabis + dextromethorphan + temazepam 1 
Mephedrone + cocaine + diazepam + MDMA + MDA + MDPV 1 
Mephedrone + cocaine + diazepam + methadone + morphine + alprazolam 1 
Mephedrone + diazepam + MDMA + MDA + dihydrocodeine + codeine 1 
Frequencies of common substances: alcohol (11); benzodiazepines (9); piperazines (6); 
cocaine (4); opiate/opioid (4); amphetamine (3); ecstasy-type (3) 
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Table 5: Post mortem levels of mephedrone found in UK mephedrone-related deaths in young 
people aged 16-24 years, reported to NPSAD by September 2013 (N = 30) 
 
 No of 
mentions 
No with 
levels 
Mephedrone blood levels 
(mg/L) 
   Mean Minimum Maximum
Mephedrone only implicated – 
sole substance in PM 
4 2 1.745 0.190 3.300 
Mephedrone only implicated – 
multiple substances in PM  
8* 6 1.372 0.070 2.240 
Mephedrone with other drugs 
and/or alcohol implicated (exc. 
previous categories) 
18 9 0.518 0.002 >2.000 
Mephedrone implicated – any 
mention 
30* 17 0.938 0.002 3.300 
* excludes an outlier of 22 mg/L 
Number of post mortem drugs: Minimum: 1; Maximum 9; Mean 3.37; Standard Deviation 
2.09. 
 
 
